

DATE	STOCK	RECOMD	ENTRY PRICE	TARGET	STOP LOSS
20.1.2025	IDBI	BUY	85	95	76
20.1.2025	GODREJCP	BUY	1185	1235	1135
20.1.2025	SBILIFE	BUY	1540	1600	1500

**NOTE –These Stocks are recommended only for short term investment (Stop Loss should be followed Daily closing basis)**

### TECHNICAL OUTLOOK

NIFTY WEEKLY CLOSE – 23203.20 (↓ 228.3 pts)

Last week Nifty opened with a gap-down at 23195 and thereafter attempted recovery. Nifty however faced resistance near 23390 and closed the week at 23203 with a loss of 228 points.

Nifty closed the week below all its key averages on daily charts. The 13-day EMA is below 55-day and 200-day EMA. Nifty is also placed below its 13-week and 55-week EMA, remains above other weekly averages. Daily as well as weekly RSI is placed below its respective averages. Nifty has formed a 'Doji' on weekly basis near its retracement level.

Going ahead, Nifty is likely to face resistance near 23300-23450. On the other hand, Nifty will seek buying support near 23100-23000.





### WEEKLY REVIEW

JANUARY 18, 2025

### WEEKLY INVESTMENT IDEAS REVIEW

DATE	STOCK	RECOMD	ENTRY PRICE	TARGET	STOP LOSS	TODAY CLOSE	NET CHANGE (%)	REMARK
13.1.2025	BAJAJFINSV	BUY	1700	1745	1660	1680.65	-1.15	Exit (High 1730)
13.1.2025	INFY	BUY	1965	2005	1930	1815.45	-8.24	Stop loss hit
13.1.2025	TATACONS	BUY	972	1005	940	954.45	-1.84	Stop loss hit

### WEEKLY MARKET REVIEW

#### Market drops for 2nd week in a row

The key equity indices traded with significant losses during the week, declining for the second straight consecutive week. The ongoing earnings season will play a critical role in determining the market's direction. Disappointing corporate earnings could prolong the negative sentiment and deepen the market's decline.

In the week ended on Friday, 17 January 2025, the S&P BSE Sensex slumped 759.58 points or 0.98% to settle at 76,619.33. The Nifty 50 index tumbled 228.30 points or 0.97% to settle at 23,203.20. The BSE Mid-Cap index fell 0.01% to close at 43,761.23. The BSE Small-Cap index plummeted 0.78% to end at 52,311.31.

Avenue Supermart's declined 2.05%. The consolidated net profit increased 4.8% to Rs 723.72 crore in Q3 FY25 as compared with Rs 690.61 crore in Q3 FY24. Net sales jumped 17.7% YoY to Rs 15,972.55 crore.

HCL Technologies tanked 10.33%. Its consolidated net profit jumped 8.41% to Rs 4,591 crore on 3.56% increase in net sales to Rs 29,890 crore in Q3 FY25 over Q2 FY25. In FY25 guidance, the CC revenue growth expected to be between 4.5%- 5.0% YoY.

Reliance Industries rallied 4.75%. It reported a 12% y-o-y increase in consolidated net profit to a record high of Rs 21,930 crore in Q3FY25. This strong performance was driven by robust growth across its key business segments: digital services, retail, and oil-to-chemicals.

Axis Bank tumbled 4.76%. Its standalone net profit increased 3.83% to Rs 6,303.77 crore on 10.17% jump in total income to Rs 36,926.14 crore in Q3 FY25 y-o-y.

Infosys declined 7.71%. The IT major reported 4.61% rise in consolidated net profit to Rs 6,806 crore on a 1.89% increase in revenues to Rs 41,764 crore in Q3 FY25 over Q2 FY25. The IT major reported strong Q3

earnings, exceeding market expectations. However, a foreign brokerage predicted a 1% sequential revenue decline in Q4, citing factors like potential reductions in third-party items or cautious management positioning.

LTIMindtree fell 3.87%. The company's consolidated net profit slipped 13.18% to Rs 1,086.7 crore in Q3 FY25 as compared with Rs 1,251.6 crore in Q2 FY25. Revenue from operations increased 2.36% QoQ to Rs 9,660.9 crore during the quarter.

Aether Industries fell 4.8%. The company reported 148.94% surge in consolidated net profit to Rs 43.39 crore on 41.4% rise in revenue from operations to Rs 219.68 crore in Q3 FY25 over Q3 FY24.

Bharat Petroleum Corporation slipped 1.42%. The firm informed that it has executed a loan agreement of Rs 31,802 crore with State Bank of India consortium, to finance the projects planned at Bina on 16 January 2024.

CG Power and Industrial Solutions advanced 2.64% after the company informed about the grant of subsidy of Rs 3,501 crore from the Government of India for setting up semiconductor assembly facility.

Amal hit an upper circuit of 20% after the company's consolidated net profit zoomed to Rs 16.53 crore in Q3 FY25 as compared with Rs 2.26 crore posted in Q3 FY24. Revenue from operations surged 77% to Rs 45.79 crore in Q3 FY25 as compared with Rs 25.87 crore in Q3 FY24.

AstraZeneca Pharma India rose 0.61%. The firm received approval from the Central Drugs Standard Control Organisation to import pharmaceutical formulations of eculizumab concentrate, marketed as Soliris. Source: [www.capitalmarket.com](http://www.capitalmarket.com)



### SAJAG SECURITIES PVT. LTD.

MEMBER: NATIONAL STOCK EXCHANGE OF INDIA LTD.

MEMBER: BOMBAY STOCK EXCHANGE LTD.

DEPOSITORY PARTICIPANT: NATIONAL SECURITIES DEPOSITORY LTD.

DEPOSITORY PARTICIPANT: CENTRAL DEPOSITORY SERVICES LTD.

33/15 - B, KARVE ROAD, REGENT CHAMBERS, PUNE - 411004, TEL: 91-20-66014737, FAX: 91-20-25302555

email: [business@sajag.co.in](mailto:business@sajag.co.in) / [investorgrievance@sajag.co.in](mailto:investorgrievance@sajag.co.in)

NSE TM ID - 07549

BSE TM ID - 3105

NSDL DP ID: IN303647

CDSL DP ID: 12062400

SEBI Regn. No. INZ000221337

**Disclosure:** This report is issued by Sajag Securities Pvt. Ltd. (SSPL), a stock broking company, which is regulated by SEBI and its research activities are as per SEBI Guidelines for Research Analysts December 2014. Registration Number: INH000001923. This report is prepared and distributed by SSPL for information purpose only. SSPL and the research analyst(s) who prepared this report do not have any long or short positions in derivatives markets in any of the above mentioned securities. SSPL or the research analyst(s) do not have ownership of 1% or more in the company. The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and/or securities, that the analyst(s) have no known material conflict of interest and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific views or recommendations contained in this research report.

**Disclaimer:** Neither the information contained herein nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security or investment or derivatives. The information and opinions contained in the report were considered by SSPL to be valid when published. The report also contains information provided to SSPL by third parties. The source of such information will usually be disclosed in the report. While SSPL has taken all responsible steps to ensure that this information is correct, SSPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his/her own risk and SSPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily a guide to future performance. The report does not have regard to the specific investment objective, financial situation and the particular needs of any specific person who may receive this report. Investor must undertake independent analysis with their own legal, tax and financial advisors and reach their own decision regarding the appropriateness of investing in any securities or investment strategies discussed and recommended in this report and should understand that statements regarding future prospects may not be realized. In no circumstances be it used or considered as an offer to sell or a solicitation of any offer to buy or sell the securities mentioned in it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which we believe reliable. SSPL does not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice. The target prices mentioned in the report are based on certain assumptions as of the date appearing in the material and may be subject to change from time to time without notice.